179 related articles for article (PubMed ID: 21970555)
1. Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.
Rasmussen TA; Tolstrup M; Melchjorsen J; Frederiksen CA; Nielsen US; Langdahl BL; Østergaard L; Laursen AL
BMC Infect Dis; 2011 Oct; 11():267. PubMed ID: 21970555
[TBL] [Abstract][Full Text] [Related]
2. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM;
AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917
[TBL] [Abstract][Full Text] [Related]
3. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
Campo R; DeJesus E; Bredeek UF; Henry K; Khanlou H; Logue K; Brinson C; Benson P; Dau L; Wang H; White K; Flaherty J; Fralich T; Guyer B; Piontkowsky D
Clin Infect Dis; 2013 Jun; 56(11):1637-45. PubMed ID: 23362296
[TBL] [Abstract][Full Text] [Related]
4. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Martínez E; Arranz JA; Podzamczer D; Loncá M; Sanz J; Barragán P; Ribera E; Knobel H; Roca V; Gutiérrez F; Blanco JL; Mallolas J; Llibre JM; Clotet B; Dalmau D; Segura F; Arribas JR; Cosín J; Barrufet P; Casas E; Ferrer E; Curran A; González A; Pich J; Cruceta A; Arnaiz JA; Miró JM; Gatell JM;
J Acquir Immune Defic Syndr; 2009 Jul; 51(3):290-7. PubMed ID: 19398921
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
Post FA; Moyle GJ; Stellbrink HJ; Domingo P; Podzamczer D; Fisher M; Norden AG; Cavassini M; Rieger A; Khuong-Josses MA; Branco T; Pearce HC; Givens N; Vavro C; Lim ML
J Acquir Immune Defic Syndr; 2010 Sep; 55(1):49-57. PubMed ID: 20431394
[TBL] [Abstract][Full Text] [Related]
6. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.
Rasmussen TA; Jensen D; Tolstrup M; Nielsen US; Erlandsen EJ; Birn H; Østergaard L; Langdahl BL; Laursen AL
PLoS One; 2012; 7(3):e32445. PubMed ID: 22479327
[TBL] [Abstract][Full Text] [Related]
7. Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.
Calza L; Magistrelli E; Danese I; Colangeli V; Borderi M; Bon I; Re MC; Mancini R; Conti M; Motta R; Viale P
Curr HIV Res; 2016; 14(1):61-70. PubMed ID: 26531764
[TBL] [Abstract][Full Text] [Related]
8. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
9. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir.
Padilla S; Masiá M; García N; Jarrin I; Tormo C; Gutiérrez F
BMC Infect Dis; 2011 Feb; 11():40. PubMed ID: 21294867
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
[TBL] [Abstract][Full Text] [Related]
12. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Sax PE; Tierney C; Collier AC; Daar ES; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Feinberg J; Tashima K; Murphy RL; Fischl MA;
J Infect Dis; 2011 Oct; 204(8):1191-201. PubMed ID: 21917892
[TBL] [Abstract][Full Text] [Related]
13. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
Sax PE; Tierney C; Collier AC; Fischl MA; Mollan K; Peeples L; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Koletar SL; Johnson VA; Geiseler PJ; Daar ES;
N Engl J Med; 2009 Dec; 361(23):2230-40. PubMed ID: 19952143
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
Kumar P; DeJesus E; Huhn G; Sloan L; Small CB; Edelstein H; Felizarta F; Hao R; Ross L; Stancil B; Pappa K; Ha B;
BMC Infect Dis; 2013 Jun; 13():269. PubMed ID: 23741991
[TBL] [Abstract][Full Text] [Related]
15. Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir.
Masiá M; Padilla S; Robledano C; López N; Ramos JM; Gutiérrez F
AIDS Res Hum Retroviruses; 2012 Mar; 28(3):242-6. PubMed ID: 21639815
[TBL] [Abstract][Full Text] [Related]
16. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.
Fisher M; Moyle GJ; Shahmanesh M; Orkin C; Kingston M; Wilkins E; Ewan J; Liu H; Ebrahimi R; Reilly G;
J Acquir Immune Defic Syndr; 2009 Aug; 51(5):562-8. PubMed ID: 19561519
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.
Wohl DA; Arnoczy G; Fichtenbaum CJ; Campbell T; Taiwo B; Hicks C; McComsey GA; Koletar S; Sax P; Tebas P; Ha B; Massengale K; Walsh K; Stein JH
Antivir Ther; 2014; 19(2):141-7. PubMed ID: 23985706
[TBL] [Abstract][Full Text] [Related]
18. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Haskelberg H; Hoy JF; Amin J; Ebeling PR; Emery S; Carr A; STEAL Study Group
PLoS One; 2012; 7(6):e38377. PubMed ID: 22719882
[TBL] [Abstract][Full Text] [Related]
19. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Melbourne K; Ha B; Brown TT; Bloom A; Fedarko N; Sax PE
AIDS; 2012 Jul; 26(11):1371-85. PubMed ID: 22546988
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
Pammi M; Arumainayagam J; Kumari B; Ahmed-Jushuf I; Carlin EM; Chandramani S; Riddell L; Ghanem M; Das S
Int J Clin Pract; 2013 Sep; 67(9):922-3. PubMed ID: 23952469
[No Abstract] [Full Text] [Related]
[Next] [New Search]